FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D C	20540
wasiiiigton,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Cadoret-Manier Onaiza				2. Issuer Name <b>and</b> Ticker or Trading Symbol Ventyx Biosciences, Inc. [ VTYX ]								ck all applic	able)	g Pers	son(s) to Iss				
(Last) (First) (Middle) C/O VENYTX BIOSCINECES, INC.				3. Date of Earliest Transaction (Month/Day/Year) 01/11/2023									Officer below)	(give title		Other (s below)	pecify		
662 ENCINITAS BLVD, SUITE 250					4. If Amendment, Date of Original Filed (Month/Day/Year)							$\dashv$	6. Individual or Joint/Group Filing (Check Applicable						
(Street) ENCINI	ΓAS C	A	92024									Line)							
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,			Code (Instr. 5)			4 and Securitie Beneficia		es Form ally (D) of Following (I) (II		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code V Amount (A) or (D)			Pr	ice	Transact (Instr. 3 a	action(s)			(III3ti. 4)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative   Conversion   Date   Execution Date,   Security   or Exercise   (Month/Day/Year)   if any			Co	ansaction of ode (Instr. Derivative		Expiration Date (Month/Day/Year)			7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		Derivative Security		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				Co	ode V	,	(A)	(D)	Date Exercisable		xpiration late	Title	Amo or Num of Shar	ber					
Stock Option (right to buy)	\$34.16	01/11/2023		I	Λ		12,880		(1)	0	1/11/2033	Common Stock	12,8	380	\$0.00	12,880	)	D	

## **Explanation of Responses:**

1. One-thirty sixth (1/36th) of the Shares subject to the option will be scheduled to vest each month following the grant date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan) through the applicable vesting date.

## Remarks:

/s/ Christopher Krueger, as Attorney-in-Fact

\*\* Signature of Reporting Person Date

01/12/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).